FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington.	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burder	า									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							,												
Name and Address of Reporting Person*     Leproust Emily M.				2. Issuer Name <b>and</b> Ticker or Trading Symbol Sema4 Holdings Corp. [ SMFR ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
<u> Leprou</u>	st Emily	<u>IVI.</u>			<u> </u>		<del></del> 80 (	-arbe I	_ U111	)		2	Director			10% Ow	ner		
(Last) (First) (Middle)					Date of Earliest Transaction (Month/Day/Year)						$\dashv$	Officer ( below)	give title		Other (sp below)	ecify			
C/O SEMA4 HOLDINGS CORP.				07/22/2021															
333 LUDLOW STREET, NORTH TOWER, 8TH FL.																			
					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street)												1 1		ed by One	Repor	ting Person			
STAMFO	ORD C	Т	06902									Form filed by More than One Reporting Person				ng			
(City)	(9	State)	(Zip)																
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date			2. Transa Date (Month/Da	Execution Date,			3. Transaction Code (Instr. 3, 4 a Code (Instr. 3)			d (A) or : 3, 4 and 5)	5. Amount Securities Beneficial Owned Fo	Form (D) o		Direct Indirect B	7. Nature of Indirect Beneficial Ownership				
								Code	v	Amount	(A) or (D)	Price	Reported Transactio (Instr. 3 ar			(1	nstr. 4)		
Class A Common Stock 07/22				07/22/	2021			C <sup>(1)</sup>	C <sup>(1)</sup> 25,000 A		\$0.00	25,0	25,000		D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Code	nsaction Derivative E		6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title and Am of Securities Underlying Derivative Sect (Instr. 3 and 4)			ies g e Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				
				Code	v V	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)					
Class B Common Stock	(1)	07/22/2021		C <sup>(1)</sup>			25,000	(1)		(1)		(1)	Class A Common Stock	25,000	(1)	0		D	
Private Placement	\$11.5	07/22/2021		A <sup>(2)</sup>		166,666		(2)		(2)	Class A Common	166,666	\$11.5	166,66	66	D			

## **Explanation of Responses:**

- 1. In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-forone basis.
- 2. In connection with the consummation of the Business Combination, all of the private placement warrants of CMLS held by the Reporting Person, which previously entitled the Reporting Person to purchase one share of CMLS's Class A Common Stock at a price of \$11.50 per whole share at any time commencing on the later of 12 months from the closing of CMLS's initial public offering or 30 days after the completion of an initial business combination of CMLS, were converted into private placement warrants of Issuer (each a "New Private Placement Warrant") simultaneously with the closing of the Business Combination, with each whole New Private Placement Warrant entitling the holder thereof to the right to purchase one share of Issuer's Class A Common Stock.

## Remarks:

/s/ Daniel Clark, Attorney-in-07/26/2021 **Fact** 

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of Shawn Assad, and Daniel Clark as his or her true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as a representative of Sema4 Holdings Corp (the "Company"), any and all Form ID, or Form 3, 4 or 5 reports and any amendments thereto required to be filed by the undersigned in accordance with Section 16(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and the rules thereunder with respect to transactions in the Company's securities;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form ID, or Form 3, 4 or 5 report and any amendments thereto and timely file such reports with the U.S. Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney in-fact on behalf of the undersigned, pursuant to this Power of Attorney, shall be in such form and shall contain such terms and conditions as such attorney in-fact may approve in his or her discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform each and every act and thing whatsoever requisite, necessary, and proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or his or her substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that no such attorney in-fact, in serving in such capacity at the request of the undersigned, is hereby assuming, nor is the Company hereby assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

The undersigned agrees that each such attorney-in-fact may rely entirely on information furnished orally or in writing by the undersigned to each such attorney-in-fact. The undersigned also agrees to indemnify and hold harmless the Company and each such attorney-in-fact against any losses, claims, damages or liabilities (or actions in these respects) that arise out of or are based on any untrue statement or omission of necessary facts in the information provided by the undersigned to such attorney-in-fact for purposes of executing, acknowledging, delivering and filing Forms 3, 4 or 5 (including amendments thereto) and agrees to reimburse the Company and each such attorney-in-fact for any legal or other expenses reasonably incurred in connection with investigating or defending against any such loss, claim, damage, liability or action.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Form 3, 4 or 5 reports with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 14th day of July, 2021.

/s/ Emily M. Leproust